-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
Trials of two Ebola treatments to start in DRC next week: WHO
Trials of two separate potential treatments to fight the deadly Ebola outbreak in the Democratic Republic of Congo are expected to begin next week, the World Health Organization said on Wednesday.
A total of 1,048 Ebola cases, including 277 deaths, have been confirmed in DR Congo since the outbreak was declared on May 15 -- although many experts believe the true toll is significantly higher.
This outbreak is down to the rare Bundibugyo species of Ebola virus -- for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus said Wednesday that "preparations are now complete for a trial of two therapeutics that's expected to start in DRC next week".
The trial, he said, would evaluate whether the monoclonal antibody MBP134 and the antiviral drug remdesivir "can help to reduce mortality in patients with Bundibugyo virus -- alone, or in combination".
Tedros thanked the United States and Gilead Sciences for donating the doses needed for the trial.
The trials will start at a hospital in DRC's northeastern Ituri province -- where the vast majority of cases have been detected -- Vasee Moorthy, who leads the WHO's research and development blueprint arm, told AFP.
The numbers of patients required would depend of how effective the therapeutics appear to be: the more effective they are, the fewer patients who would be needed, Moorthy said.
Between 500 to 1,000 people were expected to take part, he added.
Moorthy said preparations were all but complete, and the trials should provide answers as to whether each treatment, as well as both in combination, were safe and effective.
Tedros said the WHO and its partners were working closely with affected communities "to inform and involve them in the trial".
"We are also working to ensure the communities have access to the therapeutics, should they prove safe and efficacious," he said.
Tedros said the trial would be conducted by the WHO and a consortium of partners, including DRC's National Institute for Biomedical Research, the Alliance for International Medical Action (ALIMA) and Oxford University.
- Outbreak outpacing response -
The WHO chief hailed the ramping up of the Ebola response.
Over the past five weeks, the number of treatment beds had gone up from 10 to more than 500, while testing capacity in the DRC has gone up from 30 a day to more than 3,000, he said.
But he stressed that efforts to rein in the virus still faced "major challenges".
"The outbreak is continuing to outpace the response," he warned.
Capacity at treatment and isolation centres was still insufficient, while financial support for fighting the outbreak was lagging, Tedros said.
Also proving difficult, he said, was ensuring safe and dignified burials of the highly infectious bodies of those who have died from the virus, which spreads through close contact and infected bodily fluids.
Tedros voiced particular concern that contact tracing was still not at the level needed.
More than 8,200 contacts of cases have been traced -- a rate of just over 70 percent, but still short of the 95 percent target thought necessary to get on top of the virus.
Tedros said one thing hampering contact tracing efforts was the "reduced incentive" of having no vaccine to offer people coming forward -- unlike previous outbreaks with the more common Zaire strain.
Affected daily labourers for instance faced a stark choice, he said.
If they identify themselves as contacts, "they don't get vaccines", but still risk being placed in quarantine, so "they can't have even (earn) their daily bread", Tedros pointed out.
The WHO and the African Union's health agency have a joint continental preparedness and response plan which is seeking $518 million.
A.Williams--AT